Eric H. Bjerkholt
2018 - Aimmune Therapeutics
In 2018, Eric H. Bjerkholt earned a total compensation of $2.1M as Chief Financial Officer at Aimmune Therapeutics, a 45% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $175,500 |
|---|---|
| Option Awards | $1,200,251 |
| Salary | $411,667 |
| Stock Awards | $319,406 |
| Other | $2,000 |
| Total | $2,108,824 |
Bjerkholt received $1.2M in option awards, accounting for 57% of the total pay in 2018.
Bjerkholt also received $175.5K in non-equity incentive plan, $411.7K in salary, $319.4K in stock awards and $2K in other compensation.
Rankings
In 2018, Eric H. Bjerkholt's compensation ranked 5,451st out of 14,244 executives tracked by ExecPay. In other words, Bjerkholt earned more than 61.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,451 out of 14,244 | 62nd |
Division Manufacturing | 2,060 out of 5,765 | 64th |
Major group Chemicals And Allied Products | 755 out of 2,128 | 65th |
Industry group Drugs | 633 out of 1,817 | 65th |
Industry Pharmaceutical Preparations | 487 out of 1,391 | 65th |
Source: SEC filing on April 10, 2019.
Bjerkholt's colleagues
We found five more compensation records of executives who worked with Eric H. Bjerkholt at Aimmune Therapeutics in 2018.
2018
Jayson Dallas
Aimmune Therapeutics
Chief Executive Officer
2018
Douglas Sheehy
Aimmune Therapeutics
General Counsel
2018
Daniel Adelman
Aimmune Therapeutics
Chief Medical Officer
2018
Stephen Dilly
Aimmune Therapeutics
Chief Executive Officer
2018
Susan Barrowcliffe
Aimmune Therapeutics